Photo from wikipedia
Analysis of serum cytokine levels in Wiskott–Aldrich syndrome patients pre‐ and post‐ treatment reveals IL‐18 as a stable and reliable marker of inflammation. Definitive stem cell treatment with good myeloid… Click to show full abstract
Analysis of serum cytokine levels in Wiskott–Aldrich syndrome patients pre‐ and post‐ treatment reveals IL‐18 as a stable and reliable marker of inflammation. Definitive stem cell treatment with good myeloid correction correlates with resolution of inflammation and reduction of circulating IL‐18, highlighting the importance of actin cytoskeletal regulation of myeloid cells in control of inflammation.
Keywords:
potential inflammation;
inflammation biomarker;
biomarker wiskott;
inflammation;
aldrich syndrome;
wiskott aldrich
Journal Title: European Journal of Immunology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Immunology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!